Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain

A Phase I Study to Determine the Dose of Methadone as a First Line Agent in the Treatment of Chronic Neuropathic Cancer Pain

RATIONALE: Methadone hydrochloride may reduce chronic neuropathic pain in patients with cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of methadone hydrochloride as first-line therapy in treating patients with chronic neuropathic cancer pain.

Study Overview

• Status: Terminated
• Conditions: Pain; Unspecified Adult Solid Tumor, Protocol Specific; Sleep Disorders; Nausea and Vomiting
• Intervention / Treatment: Drug: methadone hydrochloride; Other: questionnaire administration; Procedure: management of therapy complications

Detailed Description

OBJECTIVES:

Primary

• To determine the optimum starting dose (defined as the dose that does not require modification within the first 4 days of treatment for lack of efficacy or the occurrence of adverse events) of methadone hydrochloride as a first-line opioid treatment in patients with chronic neuropathic cancer pain.

Secondary

• To assess the number and timing of breakthrough analgesic usage.
• To assess the number of episodes of breakthrough pain.
• To assess the total daily dose of methadone hydrochloride.
• To assess the average pain score.
• To determine the safety and adverse event profile of methadone hydrochloride as a first-line opioid in the treatment of chronic neuropathic cancer pain.
• To assess the frequency and severity of sleep disturbance associated with the use of methadone hydrochloride.
• To determine the feasibility of recruiting patients with chronic neuropathic cancer pain in a reasonable time frame for a future phase III study of methadone hydrochloride vs morphine.

OUTLINE: This is a multicenter study. Patients are assigned to a group according to their average daily dosage of morphine-equivalent for the 3 full days prior to study entry (≤ 45 mg/day OR > 45 but ≤ 75 mg/day).

Patients receive oral methadone hydrochloride at various doses every 8 hours. Patients also may receive breakthrough oral methadone hydrochloride every 2 hours, as needed, for up to 6 breakthrough analgesics per day. Treatment continues for up to 35 days. Treatment stops if the patient has well-controlled pain or experiences intolerable side effects.

Patients complete the Short-Form McGill Pain Questionnaire at baseline. Patients rate their pain according to questions from the Brief Pain Inventory on a scale of 0 (no pain) to 10 (worst pain imaginable) to best describe pain at its worst in the last 24 hours, pain at its least in the last 24 hours, pain on average, and pain right now; record the number and timing of breakthrough analgesic usage, the number of episodes of breakthrough pain, and the total daily dose of methadone hydrochloride; and complete nausea and sleep assessments once daily on days 1-14.

After completion of study treatment, patients are followed at 4, 6-7, and 28 days.

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 1

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 1Z2
      • Cross Cancer Institute
  • British Columbia
    • Kelowna, British Columbia, Canada, V1Y 5L3
      • BCCA - Cancer Centre for the Southern Interior
    • Vancouver, British Columbia, Canada, V5Z 4E6
      • BCCA - Vancouver Cancer Centre
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3E 0V9
      • CancerCare Manitoba
  • Ontario
    • Kingston, Ontario, Canada, K7L 5P9
      • Cancer Centre of Southeastern Ontario at Kingston
    • Toronto, Ontario, Canada, M5G 2M9
      • Univ. Health Network-Princess Margaret Hospital
  • Quebec
    • Montreal, Quebec, Canada, H2W 1S6
      • McGill University - Dept. Oncology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

DISEASE CHARACTERISTICS:

• Patients diagnosed with cancer and experiencing chronic neuropathic pain syndrome

  • Pain syndrome diagnosed by the investigator
  • Pain syndrome related to the effects of cancer or its treatment (i.e., chemotherapy, radiotherapy, and surgery)

  • Meets 1 of the following criteria:

    • Need to be started on strong opioids
    • Require an increase in opioid dose and are currently taking ≤ 75 mg of total daily dose of oral morphine equivalent
• Experiencing pain for ≥ 4 weeks with an average pain score of ≥ 4 or a worst pain score of ≥ 5 (using the 0-10 Brief Pain Inventory Scale) during the past 24 hours
• Requires strong opioids to control pain and is using an oral morphine-equivalent dose of 0-75 mg per day, on average, including breakthrough analgesia, within the past 3 full calendar days
• Mixed pain syndrome allowed provided the neuropathic component is the predominant pain

• Meets 1 of the following criteria:

  • Receiving concurrent chemotherapy but the chronic neuropathic pain is not related to this treatment and is not expected to improve or worsen because of this therapy
  • Received prior chemotherapy but discontinued treatment, has not received chemotherapy within the past 7 days, and no further chemotherapy is planned
  • No prior chemotherapy

PATIENT CHARACTERISTICS:

• Karnofsky performance status 40-100%
• ALT and AST ≤ 3 times upper limit of normal (ULN)
• Creatinine ≤ 2 times ULN
• No other known laboratory abnormality that, in the investigator's opinion, would contraindicate study participation
• Not pregnant or nursing
• Fertile patients must use effective contraception
• Mini-Mental State Examination score ≥ 25/30
• Able to speak, read, and write in either English or French
• Willing to complete study diary and questionnaires
• Available for study treatment and follow up (i.e., within reasonable geographical limits of the participating center)
• Able to swallow and tolerate oral medications
• Patients with prior exposure to methadone hydrochloride must be able to tolerate it
• No intractable nausea and vomiting

• No presence or history of unstable disease or condition that would, in the investigator's opinion, preclude patient participation in study treatment, such as:

  • Head injury
  • Increased intracranial pressure
  • Uncontrolled seizures
  • Uncontrolled asthma
  • Decompensated chronic obstructive pulmonary disease
  • Untreated prostate hypertrophy
  • Acute abdominal conditions
  • Untreated hyperthyroidism and Addison disease
  • Increased cerebrospinal fluid pressure
  • Urethral stricture
  • Severe cardiac arrhythmias (especially prolonged QT interval)
  • Symptomatic hypotension
  • Toxic psychosis
  • Cor pulmonale
  • Sleep apnea
  • Severe obesity
  • Kyphoscoliosis
  • Myxedema
  • Central nervous system depression
  • Coma
• No history of significant alcohol, analgesic, or narcotic substance abuse within the past 6 months
• Able physically and mentally to answer questions and comply with study treatment
• No patient who lives alone and cannot access at least 1 caregiver who can monitor on a daily basis at home

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• More than 3 weeks since prior radiopharmaceutical treatment or radiotherapy
• Concurrent co-analgesics and medications that can affect methadone hydrochloride metabolism allowed provided patients have been on a stable dose for the past 3-5 days and ≥ 5 half lives have passed since any change in dose
• Not scheduled to start chemotherapy during the study treatment
• Not planning on starting or discontinuing medication associated with modified methadone hydrochloride clearance during study treatment
• No concurrent therapeutic procedure that is likely to influence pain intensity during the study period
• No concurrent other opioid medications
• No other concurrent methadone hydrochloride

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Arm A: Methadone; Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day) Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)	Drug: methadone hydrochloride; Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day) Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 3mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) OR Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day); Other: questionnaire administration; within 48 hours of registration; Procedure: management of therapy complications; if required
Active Comparator: Arm B: Methadone; Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)	Drug: methadone hydrochloride; Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day) Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 3mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) OR Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day) Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day); Other: questionnaire administration; within 48 hours of registration; Procedure: management of therapy complications; if required

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Optimum starting dose	28 days

Secondary Outcome Measures

Outcome Measure	Time Frame
Pain control as assessed by the number and timing of breakthrough analgesics, the number of episodes of breakthrough pain, the total daily dose of methadone, and the average pain scores	28 days
Adverse events (including respiratory depression) according to NCI CTCAE v3.0 criteria	28 days
Frequency and severity of sleep disturbance from pain	28 days
Feasibility of recruiting patients	28 days

Collaborators and Investigators

• Sponsor: NCIC Clinical Trials Group
• Investigators: Study Chair: Bruno Gagnon, MD, MSC, McGill Cancer Centre at McGill University; Study Chair: Ray Viola, Queen's University

Study record dates

Study Major Dates

• Study Start (Actual): June 17, 2010
• Primary Completion (Actual): January 6, 2012
• Study Completion (Actual): January 6, 2012

Study Registration Dates

• First Submitted: June 27, 2009
• First Submitted That Met QC Criteria: June 27, 2009
• First Posted (Estimated): June 30, 2009

Study Record Updates

• Last Update Posted (Actual): February 12, 2024
• Last Update Submitted That Met QC Criteria: February 9, 2024
• Last Verified: April 1, 2020

More Information

Terms related to this study

• Keywords: unspecified adult solid tumor, protocol specific; pain; sleep disorders; nausea and vomiting
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Pain; Neurologic Manifestations; Signs and Symptoms, Digestive; Nausea; Vomiting; Sleep Wake Disorders; Parasomnias; Cancer Pain; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Respiratory System Agents; Antitussive Agents; Methadone
• Other Study ID Numbers: SC22; CAN-NCIC-SC22 (Registry Identifier: PDQ); CDR0000641372 (Other Identifier: PDQ)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No